Boston Scientific (NYSE:BSX) said last week that it enrolled the first patient in a pivotal trial to evaluate its below-the-knee drug-eluting stent in patients with critical limb ischemia.
The peripheral stent is the first of its kind to undergo the FDA’s breakthrough device program, according to the medtech giant.
Get the full story at our sister site, Drug Delivery Business News.
The post Boston Scientific launches trial for drug-eluting peripheral stent appeared first on MassDevice.
from MassDevice https://ift.tt/2CLTs4y
Cap comentari:
Publica un comentari a l'entrada